The companion diagnostics market is becoming increasingly important as healthcare moves from broad treatment approaches toward precision medicine and biomarker-guided therapies. The market was valued at USD 9.6 billion in 2025 and is projected to grow from USD 10.3 billion in 2026 to USD 20.1 billion by 2033, registering a CAGR of 10.1% from 2026 to 2033. Increasing demand for precision medicine and the rising prevalence of cancer, cardiovascular diseases, and autoimmune disorders are strengthening the need for diagnostic tests that help identify appropriate targeted treatments.

Download a free sample copy of the Companion Diagnostics market report to understand detailed coverage and inclusions in the final report

Precision Medicine Strengthens Companion Diagnostics Demand

The transition toward personalized treatment is one of the major forces shaping the market. Instead of relying on a one-size-fits-all approach, healthcare providers increasingly use molecular and biomarker information to determine which therapies are more appropriate for individual patients.

The rising prevalence of cancer is particularly important because companion diagnostics can identify genetic mutations and other biomarkers that guide targeted therapy selection. The continued development of precision oncology is therefore increasing demand for accurate, efficient, and clinically useful diagnostic technologies.

The market is also benefiting from the increasing integration of companion diagnostics into clinical trials and pharmaceutical development. By supporting patient stratification, these tests can help researchers identify suitable participants and evaluate treatment responses more effectively.

Technology Innovation Improves Diagnostic Accuracy

Rapid advances in diagnostic technologies are creating another important growth pathway. Next-generation sequencing (NGS), polymerase chain reaction (PCR), digital pathology, artificial intelligence, and machine learning are improving biomarker identification and data interpretation.

PCR held the largest technology share at 27.7% in 2025, supported by its high specificity and sensitivity for detecting cancer biomarkers. Real-time PCR also enables efficient gene analysis and supports tumor profiling in clinical laboratories. Meanwhile, NGS is projected to record the fastest CAGR during the forecast period because it can detect low-frequency mutations, identify multiple genetic alterations, and support high-throughput analysis.

Liquid biopsy is another emerging area, enabling non-invasive analysis of circulating tumor DNA and other biomarkers. These capabilities can support real-time disease monitoring and treatment-response assessment, adding further momentum to technology-driven market development.

Oncology Remains the Core Application Area

Oncology accounted for the largest indication share, representing 56.5% in 2025. The segment is benefiting from the continuing need to identify biomarkers associated with targeted cancer therapies. Advances in NGS, immunohistochemistry, and liquid biopsy are expanding the ability to detect genetic alterations with greater precision.

The cardiovascular disease segment is expected to experience the fastest CAGR over the forecast period. Companion diagnostics are increasingly being explored for therapy selection, drug-response optimization, and risk stratification using biomarker-based approaches. Advances in genomic profiling, pharmacogenomics, and molecular diagnostics are supporting these applications.

Assays, Kits, and Reagents Lead Product Demand

Assays, kits, and reagents held the largest product and service share at 59.2% in 2025. These products are essential for detecting biomarkers that determine patient eligibility for precision treatments, particularly in oncology, cardiovascular diseases, and rare genetic disorders.

The expansion of NGS and PCR-based assays is supporting this segment by enabling rapid, accurate, and high-throughput testing. In contrast, software and services are projected to record the fastest CAGR, supported by growing demand for advanced data analysis, regulatory compliance, and test-development support.

Tissue Testing Dominates While Blood-Based Diagnostics Expand

Tissue samples represented the largest sample-type segment with a 62.6% share in 2025. Tissue-based testing remains important for identifying genetic mutations and protein expression in solid tumors. Techniques such as immunohistochemistry, in situ hybridization, and PCR continue to support tissue-based biomarker analysis.

However, blood samples are projected to achieve the fastest CAGR. The increasing adoption of liquid biopsy is creating opportunities for minimally invasive testing, particularly where traditional tissue biopsies may be difficult to perform.

Hospitals and Pharmaceutical Companies Drive Adoption

Hospitals and physician laboratories accounted for 38.8% of the market in 2025. Their position reflects increasing adoption of advanced diagnostic technologies for cancer detection and personalized treatment. Healthcare facilities are also expanding diagnostic capabilities and developing collaborations with pharmaceutical companies.

Pharmaceutical and biotechnology companies are expected to register the fastest CAGR among end-use segments. Their growing investments in targeted therapies and biomarker-driven drug discovery are increasing the need for reliable companion diagnostics throughout clinical development and commercialization.

FAQs

What trends are shaping the companion diagnostics market?

The market is being shaped by the expansion of precision medicine, increasing use of biomarker-driven therapies, advances in NGS and PCR, liquid biopsy adoption, AI and machine learning, digital pathology, and closer integration between diagnostic developers and pharmaceutical companies.

Which segment leads the companion diagnostics market?

Assays, kits, and reagents led the product and service category with a 59.2% share in 2025, while oncology led by indication with a 56.5% share. PCR was the leading technology with 27.7%, tissue samples held 62.6%, and hospitals and physician laboratories accounted for 38.8% by end use in 2025.

Key Companion Diagnostics Companies:

·        QIAGEN

·        Agilent Technologies, Inc.

·        Abbott

·        Thermo Fisher Scientific, Inc.

Explore the full list of profiled companies operating in this market with recent strategic initiatives

About us:
Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.